



Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset



A list of authors and their affiliations appears at the end of the paper

To investigate whether antidiabetic drugs have a biological basis to be repurposed in PD prevention, we applied a drug target Mendelian randomization framework to assess associations between genetic variation in antidiabetic drug targets and PD risk or age at onset (AAO). Instrumental variables (IVs) were derived from GWAS summary statistics on fasting glucose (FG), glycated hemoglobin (HbA1c), and gene expression data from GTEx. Apart from SGLT2 inhibitors, all other antidiabetic drugs of interest could be instrumented through our methods. Positive and negative control analyses were carried out to validate 20 IVs in the FG arm and 23 IVs in the HbA1c arm. DPP-4 inhibitors failed the positive control. GWAS summary statistics for PD risk and AAO data were sourced from the IPDGC and COURAGE-PD consortia, resulting in 42 083 cases/457 090 controls for risk and 37 103 PD cases for AAO. MR analyses showed no significant associations across consortia or in meta-analysis. These findings do not support a causal role of genetic variation in antidiabetic drug targets in PD risk or AAO.

Parkinson's disease (PD) is a neurodegenerative disorder affecting around 12 million people globally¹ with no disease-modifying treatments available². PD has a moderate genetic component, with heritability estimated at 16–36% (excluding monogenic mutations, which have higher penetrance, and account for <2–5% of cases)^{2,3}. The pathophysiology of PD involves alpha-synuclein aggregation, neuroinflammation, vesicle and synaptic transport impairment and dysfunction of mitochondria². Some of these mechanisms are not unique to PD, and using drugs already proven to work for other diseases is a promising option in PD treatment.

Type 2 diabetes (T2D) and PD share common molecular⁴ and biological pathways, such as protein accumulation, lysosomal and mitochondrial dysfunction, and chronic systemic inflammation^{5–8}. Drug repurposing or repositioning uses already existing and safety-tested drugs for new indications⁹. This is preferable compared to developing new substances due to shorter timeline for development and approval⁹. Considering that T2D and PD have biological processes in common, repurposing antidiabetic medications for PD treatment or prevention has been suggested⁶. Both traditional and recently developed antidiabetic drugs have lately been a focus of repurposing efforts for neurodegenerative diseases^{10–12}, including PD^{8,12}.

Metformin has been associated with a lower risk of PD and other neurodegenerative diseases by a range of observational studies^{13–15}. GLP-1 receptor agonists and DPP-4 inhibitors have also shown promising PD prevention results in a cohort study of diabetic patients¹⁶. According to a 2024 update of the results from PD drug clinical trials, there are 5 ongoing

trials of GLP-1 receptor agonists as disease-modifying treatment for PD¹⁷. On the other hand, a case-control study of PD risk in diabetes patients found no association between a range of diabetes medications (insulins, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists and metformin) and PD, apart from thiazolidinediones – which was associated with a reduced PD risk¹⁸. Additionally, SGLT2 inhibitors have been discussed as a potentially viable repurposing alternative¹⁹. Thus, observational evidence on potential repurposing of antidiabetic drugs in PD prevention is conflicting.

Mendelian randomization (MR) is an analytical method that uses genetic variants (such as single-nucleotide polymorphisms, SNPs) as instrumental variables (IVs) to proxy environmental exposures, minimizing confounding and reverse causation in observational studies^{20,21}. Drug target MR is a specialized form of MR often applied with the aim to explore repurposing opportunities²⁰. For IVs to be valid in drug target MR, they should meet three key assumptions: 1) relevance (the IVs are associated with the exposure), 2) independence (IVs are not associated with confounders), and 3) exclusion restriction (no horizontal pleiotropy, meaning IVs influence the outcome only through the drug target)²⁰.

MR evidence on potential repurposing of antidiabetic drugs in PD prevention is inconclusive. Metformin has been linked to reduced PD risk in a drug target MR study²², hypothetically due to mechanisms such as neuroprotection²² or regulation of mitochondrial activity²³. However, both metformin, GLP-1 receptor agonists, and insulin were linked to worsened motor symptoms in another drug target MR study²⁴. SGLT2 inhibitors have also been associated with increased risk for PD in a drug target MR study²⁵.

✉ e-mail: katalin.vincze@ki.se

Another MR study suggested sulfonylureas as an alternative for PD prevention²⁶, while a recent study using the same outcome data source suggested no repurposing benefit of antidiabetic drugs in general for PD prevention or treatment²⁷. Limitations of previous drug target MR studies of antidiabetic drugs in PD include that they often relied solely on existing literature or the same resources to identify and validate IVs, they focused on only a subset of antidiabetic drugs and predominantly used the same genome-wide association studies (GWAS) for PD-related outcomes.

The aim of the present study was to investigate whether antidiabetic drugs have a biological basis for repurposing as primary preventive agents against PD, applying a comprehensive IV selection process and leveraging a large-scale meta-analysis of genetic data on PD risk and AAO that had not been previously utilized for the topic of interest from the Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD) consortium^{28–30} in addition to the International Parkinson's Disease Genomics Consortium (IPDGC) data^{31,32}. This resulted in a sample of 42 083 cases and 457 090 controls for PD risk, and 37 103 cases for PD AAO.

Results

Selection of IVs

The number of IVs (SNPs) per drug class identified varied between zero (no IVs identified) and 22 (Table 1). Our biologically informed selection criteria were based on statistical significance from the GWAS summary statistics on fasting glucose (FG) or glycated hemoglobin (HbA1c) (comprising two different arms of the analysis) and gene expression data (expression quantitative trait loci – eQTL). Metformin was instrumented by one IV in the FG arm, insulin/insulin analogues by two IVs in the FG arm and one in the HbA1c arm, GLP-1 receptor agonists by three IVs in each arm, and sulfonylureas by four in the FG arm and two in the HbA1c arm. Thiazolidinediones were instrumented with the most IVs both in the FG arm ($N = 17$) and in the HbA1c arm of the study ($N = 22$). For SGLT2 inhibitors in both arms and metformin in the HbA1c arm, no IVs were identified due to SGLT2 inhibitor IV candidates not fulfilling the filtering criteria in the downstream GWASes. IVs and their corresponding genes with flanking regions per drug class are detailed in Table 1. The number of IVs was the same as the number of genes in all cases. IV alleles were harmonized such that effect alleles corresponded to negative effect estimates. F statistics were calculated for all IV sets, and results ($F > 10$) indicated that the IV sets selected had appropriate instrument strength (Supplementary Tables 1, 2).

Negative and positive controls

All IVs passed the negative control, as there were no statistically significant associations between selected IVs and childhood asthma (Fig. 1). Based on our results, the hypothesis of no association is confirmed by the lack of association found in the negative control, and thereby in line with MR assumptions. Checking for directional consistency for decreasing risk of T2D showed that IVs for thiazolidinediones, metformin (FG arm only), insulin/insulin analogues and GLP-1 receptor agonists, as well as IVs in the HbA1c arm for sulfonylureas, passed the positive control (Fig. 1). IVs for Sulfonylureas in the FG arm were a borderline case but were kept as IVs. IVs for DPP-4 inhibitors did not pass the positive control, neither in the FG nor the HbA1c arm, meaning that DPP-4 MR results do not have the same validity as the rest of the drugs. Therefore, DPP-4 F statistics were moved to be reported separately (Supplementary Table 2).

MR analyses

Meta-analyzing the IPDGC and COURAGE data, the main MR analysis (inverse variance weighted, IVW) showed no statistically significant associations between genetic variation in targets of thiazolidinediones, sulfonylureas, insulin/insulin analogues, GLP-1 receptor agonists and PD risk or AAO (Fig. 2, Supplementary Table 3). However, based on the Wald ratio model, the single IV for metformin in the FG arm (rs6598541 in the *IGF1R* gene) was significantly associated with lower PD risk (meta-analysis: $B = -2.792$, $SE = 1.285$, $p = 0.0298$) (Supplementary Table 3). Notably,

though, this statistical significance disappeared after Bonferroni correction due to testing multiple drug classes. The results remained non-significant in consortium-stratified analyses, except for the association between the single IV for metformin and PD risk in the FG arm in COURAGE-PD prior to Bonferroni adjustment (COURAGE-PD only: $B = -5.155$, $SE = 2.166$, $p = 0.017$; IPDGC only: $B = -1.509$, $SE = 1.596$, $p = 0.345$) (Supplementary Tables 4, 5). We also found that GLP-1 receptor agonist IVs unadjusted, borderline significantly increased PD risk in the FG arm, in the COURAGE-PD stratification using the IVW model ($Beta = 3.024$, $SE = 1.496$, $p = 0.043$). We found no other statistically significant results for any other MR model in any of the consortia (Supplementary Tables 3–5). Although DPP-4 inhibitor IVs failed the positive control, the corresponding non-significant, mixed directionality results are displayed in Supplementary Table 6.

Sensitivity analyses

There were large variations by different drug classes in statistical uncertainty, likely due to the varying number of IVs available per drug. We plotted post hoc sensitivity analysis scatterplots of MR slopes of the GLP-1 receptor agonists corresponding IVs, to compare MR Egger with the other models, as MR Egger results seemed different from the other three models. This is likely to be due to the low number of SNPs, and not due to instrument weakness, as confirmed by the F statistics (Supplementary Table 1). We examined the IV effect sizes for each exposure and outcome to ensure the model contained no errors (see Supplementary Fig. 1). We found no evidence of colocalization (Supplementary Table 7), in line with the MR results. Leave-one-out MR analysis on the thiazolidinediones IVs were in line with our main MR findings, thus confirming the non-significant results (Supplementary Table 8).

Discussion

To our knowledge, our drug target MR study used one of the largest GWAS samples both for PD risk and AAO by combining data from the COURAGE-PD and IPDGC consortia, resulting in 42 083 cases/457 090 controls for PD risk and 37 103 cases for PD onset. We found no evidence that genetic variation in antidiabetic drug targets reduces the risk of PD or delays its onset. This project was the first to address this question using GWAS summary statistics from the COURAGE-PD consortium. Moreover, our IV selection approach was novel, since we combined elements and publicly available resources in a unique and comprehensive way by including both the downstream biomarker and eQTL levels. While most previous studies relied on the UK Biobank^{24,26,27} for GWAS data on downstream biomarkers, we used data from a different study population (MAGIC)³³.

Our results were in line with findings of two previous antidiabetic drug target MR studies^{24,27}, but did not support others that found significant decrease^{22,26} in PD risk. Based on the IPDGC datasets, Wang et al. found no significant associations between genetic variation in antidiabetic drug targets and PD risk, AAO or PD progression²⁷. We extended these findings with additional data from the COURAGE-PD consortium^{28,29}. A difference between our study and Wang et al. was the IV selection process, as those authors used GWAS summary statistics on medication-use from the UK Biobank^{34,35}, whereas we took a biologically informed approach based on biomarkers and eQTL. The other study supporting our findings of a lack of association between genetically predicted antidiabetic drug effects and PD risk or AAO²⁴ was based on GWAS summary statistics from the FinnGen biobank and relied on IVs identified by previous studies^{11,36}. Some of these IVs were selected using downstream biomarkers¹¹, and similar to our approach, the metformin IVs were selected through a combination of biomarkers and eQTL³⁶. Yet, those authors identified metformin-related drug targets in different genes than we did³⁶. A potential explanation for this is that the mechanism of action of metformin is complex and not completely understood³⁷.

Our findings did not confirm the drug target MR findings of Storm et al., who found preliminarily positive evidence for repurposing metformin for PD prevention using the IPDGC datasets²². Storm et al.

Table 1 | Selected instrumental variables per drug class depending on the downstream biomarker (fasting glucose and glycated hemoglobin)

Drug	Fasting glucose arm			HbA1c arm		
	Gene	Gene location (in GRCh37 from Ensembl) without the +/- 2.5k base pairs flanking region	Variants	Gene	Gene location (in GRCh37 from Ensembl) without the +/- 2.5k base pairs flanking region	Variants
SGLT2 inhibitors	0	0	0	0	0	0
Metformin	IGF1R	chr 15:99192200-99507759	rs6598541	0	0	0
DPP-4 inhibitors	GLP1R	chr 6:39016574-39055519	rs6923761	DPP8	chr 15:65734801-65810042	rs11636148
Insulin/insulin analogues	IGF1R, INS	chr 15: 99192200-99507759, chr 11:2181009-2182571	rs6598541, rs3842754	INS	chr 11:2181009-2182571	rs3842756
GLP-1 receptor agonists	DGAT1, GLP1R, INS	chr 8:145539954-145550573, chr 6:39016574-39055519, chr 11:2181009-2182571	rs3757974, rs6923761, rs3842754	CDH1, INS, SREBF1	chr 16:68771128-68869451, chr 11:2181009-2182571, chr 17:17713713-17740325	rs7198799, rs3842756, rs9894257
Sulfonylureas	ABCB11, CYP1A2, INS, TPD52	chr 2:169779448-169887832, chr 15:75041185-75048543, chr 11:2181009-2182571, chr 8:80870571-81143467	rs557462, rs2960192, rs3842754, rs12541643	ABCB11, INS	chr 2:169779448-169887832, chr 11:2181009-2182571	rs853777, rs3842756
Thiazolidinediones	ABCB11, CYP1A2, DMPK, GPX1, IARS1, IGF1R, INHBE, INS, MAPRE3, NR1H3, PDIA5, PPM1G, REEP3, SKAP1, SLC2A1, TP53INP1, WFS1	chr 2:169779448-169887832, chr 15:75041185-75048543, chr 19:46272975-46285810, chr 3:49394609-49396033, chr 9: 94,972,489-95,056,038, chr 15:99192200-99507759, chr 12:57846106-57853063, chr 11:2181009-2182571, chr 2:27193480-27250064, chr 11:47269851-47290396, chr 3:122785909-122944074, chr 2:27604061-27632554, chr 10:65281123-65384883, chr 17:46210802-46507637, chr 1:43391052-43424530, chr 8:95938200-95961639, chr 4:6271576-6304992	rs557462, rs2960192, rs2070737, rs3811699, rs12353096, rs6598541, rs3741414, rs3842754, rs13020526, rs11039154, rs28661248, rs1083864, rs6479911, rs16954324, rs3729548, rs896854, rs6446479	ABCB11, AGER, ALDH8A1, APOC2, CCND2, CDH1, DPAGT1, IDE, INS, NR1H3, PDIA5, PHETA1 ^a , PKLR, PLD1, PPIL6, SLC25A20, SLC25A26, SREBF1, TBL2, TF, TMEM86B, TMPRSS6	chr 2:169779448-169887832, chr 6:32148745-32152101, chr 6:135238528-135271260, chr 19:45449243-45452822, chr 12:4382938-4414516, chr 16:68771128-68869451, chr 11:118967213-118979041, chr 10:94211441-94333833, chr 11:2181009-2182571, chr 11:47269851-47290396, chr 3:122785909-122944074, chr 12:111788483-111816899, chr 1:155259630-155271225, chr 3:171318195-171528740, chr 6:109711418-109762374, chr 3:48894369-48936426, chr 3:66119285-66438540, chr 17:17713713-17740325, chr 7:72983262-72993121, chr 3:133464800-133497850, chr 19:55738007-55741647, chr 22:37461476-37505603	rs853777, rs3130349, rs7749106, rs7257476, rs76895963, rs7198799, rs617948, rs11187019, rs3842756, rs11039154, rs28661248, rs874286, rs12067675, rs4894769, rs61318425, rs11708022, rs7630745, rs9894257, rs13232120, rs3811658, rs28678477, rs4820268

Drug class is referred to as 'Drug' in the Figures for brevity.

^a<https://www.genecards.org/cgi-bin/carddisp.pl?gene=PHETA1>.




Fig. 1 | Negative and positive control. Effect estimates refer to the outcome effect estimate (childhood asthma in panel A on top, and type 2 diabetes in Panel B on the bottom), not the effect estimates coming from the downstream biomarkers. As we were proxying antidiabetic drugs effect, the IVs were coded so that they decrease (negative effect) the two downstream traits (red: fasting glucose, purple: glycated

hemoglobin). In successful negative control (panel A), we hypothesized that the outcome is not associated with the IVs. In a successful positive control (panel B) where the outcome is type 2 diabetes, the outcome effect sizes show negative effect sizes for type 2 diabetes. Note: drug class is referred to as ‘Drug’ in the Figures for brevity.




Fig. 2 | Inverse variance weighted Mendelian randomization analyses per downstream biomarker arm (red: fasting glucose, purple: glycated hemoglobin) using meta-analysis of COURAGE-PD and IPDGC Parkinson's disease risk (panel A, left) and meta-analysis of COURAGE-PD and IPDGC Parkinson's disease age at onset

(panel B, right) outcome data. Effect estimates are log odds ratios. Note: TZD stands for thiazolidinediones, and drug class is referred to as ‘Drug’ in the Figures for brevity.

selected IVs through prefrontal cortex and blood tissue-specific eQTL and pQTL filtering of druggable genes but did not filter specifically for diabetes-related traits²². Further, our findings did not corroborate a more recent drug target MR study that reported evidence for repurposing sulfonylureas to prevent PD based on the IPDGC dataset²⁶ with IVs selection in a similar fashion to Zhao et al.²⁴, but using IVs from a study on Alzheimer's disease selected from the UK Biobank¹¹. It is important to note though, that using the same sulfonylureas IVs, these results were not reproduced in the FinnGen PD risk dataset²⁴. As we were unable to instrument genetic variation in targets of SGLT2 inhibitors, a direct

comparison with a previous drug target MR study that reported increased PD risk related to SGLT2 inhibitors²⁵ is precluded.

We found a slight signal for decreased PD risk related to a SNP in the *IGF1R* gene (Insulin-like growth factor 1 receptor), a drug target of metformin, in the FG arm before Bonferroni adjustment in COURAGE-PD and the meta-analysis. The variant has been implicated in inflammatory processes in gout³⁸, and is expressed in the heart and to a lesser extent in several other tissues, including the brain (amygdala)³⁹. Several lines of evidence support the relevance of IGF-1/IGF1R in the pathophysiology and development of PD⁴⁰.

Notably, there was very little overlap between IVs included in previous drug target MR studies on antidiabetics and PD risk and our study, which is likely explained by the different study populations of the GWAS data for downstream biomarkers, and our different approach. Only one IV in our study (rs76895963) in the *CCND2* (Cyclin D2 gene) was included in a previous study²⁷. However, two of the drug target genes in our study, *PP1L6* (Peptidylprolyl Isomerase Like 6) and *PHETA1* (PH Domain Containing Endocytic Trafficking Adaptor 1), were also GWAS hits in the COURAGE-PD risk GWAS³⁰. There was no overlap between the hits identified by one of the latest GWASes on PD risk⁴¹ and our IVs, but interestingly there was one overlapping gene: *SREBF1*, which was a novel GWAS locus corresponding to GLP-1 receptor agonists and thiazolidinediones in the HbA1c arm among our IVs.

Observational studies on antidiabetics and PD risk have reported mixed results. A meta-analysis of population-based cohort studies found decreased risk of neurodegenerative diseases related to metformin, but no association with PD¹³. SGLT2 inhibitors have shown some potential for repurposing in a population-based Korean cohort study⁴². Thiazolidinediones were associated with lower PD risk in a population-based retrospective cohort study of T2D patients in China⁴³. A meta-analysis of observational evidence from Taiwan and the UK found that pioglitazone (belonging to the thiazolidinediones drug class) was linked to decreased PD risk in a dose-response manner⁴⁴, but another meta-analysis reported no association between certain thiazolidinediones, metformin, sulfonylureas, DPP-4 inhibitors and PD risk⁴⁵. A major difference between drug target MR and observational studies is the duration of exposure. Drug target MR studies proxy lifelong exposure to the drug of interest, while observational studies usually investigate much shorter periods²⁰. Additionally, observational studies are limited by different biases, such as confounding and reverse causation, which are minimized in the MR approach.

Large-scale observational data are limited to participants with diabetes. A meta-analysis of clinical trials for repurposing newer antidiabetic drugs, also including persons with heart failure and chronic kidney disease, found decreased risk of PD related to SGLT2 inhibitors but was limited by small numbers, short follow-up and lack of exclusion of PD cases at baseline⁴⁶. Although early clinical trials of GLP-1 receptor agonists showed promising results for disease modification in PD⁴⁷, some later results showed limited clinical relevance⁴⁸, and a recent phase 3 trial of the GLP-1 receptor agonist exenatide for disease modification was negative⁴⁹.

One of the main strengths of this study was the combination of data from the COURAGE-PD and IPDGC consortia, which to our knowledge, resulted in the largest European-ancestry GWAS samples both for PD risk and AAO. Additionally, we also used data from a large-scale consortium (MAGIC) for the IV selection, in contrast to most other similar studies that relied on the UK Biobank^{24,26,27}. To ensure biological relevance in the IV selection process, i.e. that the SNP influences gene expression, we implemented an eQTL-filtering step^{20,36,50}. Furthermore, to triangulate findings, we used sensitivity analyses, including positive and negative controls, in line with current guidelines for performing and reporting drug target MR studies⁵¹, also displayed in Supplementary Fig. 2.

However, there are limitations to our study. First, we were unable to instrument SGLT2 inhibitors. Second, the outcome GWAS summary statistics were mostly based on persons of European ancestry, resulting in generalizability mainly to European ancestry populations. Further research on different populations is needed, especially considering that much of the observational evidence in favor of repurposing antidiabetic drugs for PD come from East Asia. Finally, it is important to acknowledge the general limitation stemming from the study design that despite our best efforts to follow best practice and conduct sensitivity analyses, we cannot fully exclude that there is pleiotropy at play.

In conclusion, using a drug target MR framework with a comprehensive approach to IV selection and summary statistics from a large PD GWAS sample, we found no significant association between genetic variation in antidiabetic drug targets and PD risk or AAO. These results suggest that there is no indication for repurposing any of the examined antidiabetic drugs for

primary prevention or delayed onset of PD. Future research should focus on investigating other drug classes as potential strategies for PD prevention.

Methods

Study design: drug target MR

We used a drug target MR framework to investigate whether genetic variation in antidiabetic drug targets would lower the risk or delay the onset of PD.

MR is an analytic approach in which environmental exposure is proxied through genetic variants, used as instrumental variables (IVs)^{20,21}. In contrast to conventional observational designs, MR helps to overcome issues such as unresolved confounding and reverse causation thanks to Mendel's law of independent assortment, meaning that the inheritance of genetic variants related to the trait of interest is independent of (i.e. randomized with respect to) the inheritance of other traits²¹. This makes an MR study similar to a randomized controlled trial, enabling causal inference if certain assumptions are met⁵².

Drug target MR is a specific type of MR concerned with the validation of drug targets, often with the aim to explore drug repurposing possibilities²⁰. Unlike conventional MR, which typically uses genetic variants (IVs) associated with an exposure, drug target MR restricts instruments to cis-acting variants located near or within the gene encoding the drug target. IVs should pass three assumptions in a drug target MR study²⁰: (i) *relevance assumption*, i.e. the drug affects the relevant tissues, e.g. by incorporating downstream biomarkers in IV filtering; (ii) *independence assumption*, the relationship between IVs and the outcome are independent of confounders; (iii) *exclusion restriction assumption* (or 'no horizontal pleiotropy' assumption⁵³), effects from pleiotropic mechanisms should be separate from the drug target's effect²⁰. The first assumption is testable; the remaining two are not testable, but falsifiable⁵⁴. By filtering variants within the cis-regions of relevant genes, including an eQTL step in the IV selection process, incorporating GWASes on downstream biomarkers, such as FG and HbA1c, and applying LD clumping as the final step alongside downstream biomarkers, we aimed to ensure biological relevance fulfilling the three assumptions.

Data resources

Genes linked to the antidiabetic drugs under study were identified from PubChem⁵⁵ and Drug-Gene Interaction Database (Beta version)⁵⁶. All drugs are listed in Supplementary Table 9.

To proxy antidiabetic drug effects, we used summary statistics from two GWASes from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC): one on fasting glucose (FG) and another on glycated hemoglobin (HbA1c)^{33,57}. Both datasets were restricted to European populations to harmonize with the available outcome datasets. To our knowledge, the MAGIC samples do not overlap with the outcome GWASes. For the outcomes of PD risk and age at onset (AAO), we relied on GWAS summary statistics from two consortiums for each: IPDGC^{31,32} and the COURAGE-PD consortium²⁸⁻³⁰. As there is some sample overlap between the IPDGC and COURAGE-PD, we excluded the part of the sample from COURAGE-PD that overlaps with IPDGC¹¹⁻⁴⁴. The PD risk datasets included cases and PD-free controls, while the AAO GWAS datasets only focused on PD cases with the aim to identify genetic loci associated with the variation in onset age. For our meta-analyses of these two GWASes, our sample included 42 083 cases/457 090 controls for risk and 37 103 PD cases for AAO, thus resulting in the best-powered study so far.

We also used multi-tissue eQTL data, selected from The Genotype-Tissue Expression (GTEx) Portal^{39,58}. Sample size and further details on the GWASes used and the eQTL dataset can be found in Supplementary Table 10.

Selection of IVs

The IV selection process is described in Fig. 3. We first identified a list of antidiabetic drugs for the drug classes of interest (e.g. tolazamide for sulfonylureas, exenatide for GLP-1 receptor agonists, etc., see Supplementary Table 9) and genes associated with them. We defined our IVs as SNPs. IV




Fig. 3 | Flowchart of instrumental variable selection. HbA1c stands for glycated hemoglobin, and drug class is referred to as ‘Drug’ in the Figures for brevity.

selection was divided into two parallel, downstream biomarker arms, each relating to diabetes: FG and HbA1c, corresponding to the proxied antidiabetic drug effects (lowering FG and HbA1c, respectively). The two arms were kept separate to facilitate interpretation of the results. SNPs were extracted from these two GWASes on glycemic traits in the cis-variant region of the genes (defined as ± 2500 base pairs of the gene location, similar to previous research¹¹), as well as from within the gene region. To ensure biological relevance, SNPs were then filtered requiring genome-wide significance ($p < 5 \times 10^{-8}$) in at least one of 48 tissues in the GTEx multi-tissue eQTL resource^{39,59}, since most antidiabetic drug targets are expressed across multiple tissues. We then filtered further by requiring a strong association with FG and HbA1c ($p < 0.00001$ in their respective GWASes). SGLT2 inhibitor IV candidates were lost during the latter filtering step, as they had higher p values. We used both eQTL and GWASes on downstream biomarkers to strengthen the plausibility of the relevance- and ‘no horizontal pleiotropy’ assumptions in the MR design⁵³, since having both filters helps with proxying the protein quantitative trait loci (pQTL) level^{20,36}. We then performed LD clumping of the SNPs per drug class separately in each downstream biomarker arm, retaining SNPs using the r^2 cutoff of 0.001; this LD clumping step contributed towards the independence assumption of MR IV selection²⁰. The remaining SNPs were then linked back to genes, and then to drugs whose effects the genes proxy, and finally to the overall drug classes. To ensure that the SNPs proxied antidiabetic drug effects consistently and to allow interpretation of the positive and negative control as well as MR analyses, SNPs were coded so that effect alleles lower FG and HbA1c levels, respectively. F statistics were calculated to test the strength of each IV set.

Positive and negative control

To ascertain directional consistency of genetically predicted drug effects with clinical trial evidence/drug mechanisms, we performed positive and

negative control analyses for the selected IVs per drug class¹¹ by random effects meta-analysis of individual SNP effect sizes on the control outcome.

For the positive control, we used T2D as the outcome and corresponding GWAS summary statistics from FinnGen (T2D, wide definition)⁶⁰. As the SNPs were coded so that the effect allele lowers FG and HbA1c, we expected that they would also be associated with lower risk for T2D. Therefore, drug classes with pooled estimates showing directional consistency were considered to pass the positive control.

For the negative control, childhood asthma risk was chosen as the outcome, as we hypothesized that the selected exposures and drug targets are not causally affecting childhood asthma risk. We used GWAS summary statistics on childhood asthma (age <16) from the UK Biobank through the IEU OpenGWAS project⁶¹. In line with our hypothesis of no relationship between our IVs and risk for childhood asthma, drug classes that pass the negative control should have a pooled estimate showing no significant effect.

MR analyses

For the MR analyses, our outcome GWAS summary statistics were PD risk and PD AAO. We used 5 different MR models (Wald ratio, inverse variance weighted [IVW], MR Egger, weighted mean and weighted median) and conducted analyses for each outcome by meta-analyzing SNPs from the two consortia using fixed-effects models, plus analyses stratified by consortium. The analyses were kept separate depending on the downstream biomarker used (FG or HbA1c). LD clumping and MR analyses were carried out using the TwoSampleMR package in R (version 0.6.14)⁶².

All analyses were conducted in R (versions 4.2.3 and R 4.4.0)⁶³. Genomic locations corresponded to the GRCH37/hg19 genome assembly via the R/Bioconductor package biomart^{64,65}.

Sensitivity analyses

To ensure the validity of our results, we conducted sensitivity analyses. These included post-analysis scatterplots to investigate effect sizes, confidence intervals and MR model slopes further where we deemed results as unusual or extreme. We have also conducted colocalization analysis where MR signals were the most pronounced, to be able to answer the question whether the exposure signal and the outcome signal are truly driven by the same variant or whether it only appears so due to LD⁶⁶. Since thiazolidinediones had the highest number of IVs, leave-one-out MR using IVW was also conducted to investigate whether there are any outliers.

Data availability

Apart from COURAGE-PD datasets, all data used are publicly available. For details, see Supplementary Table 10.

Code availability

R codes are available on Zenodo (<https://doi.org/10.5281/zenodo.19388329>), apart from the codes working directly on COURAGE-PD data.

Received: 20 January 2026; Accepted: 13 May 2026;

Published online: 28 May 2026

References

- Steinmetz, J. D. et al. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet Neurol.* **23**, 344–381 (2024).
- Bloem, B. R., Okun, M. S. & Klein, C. Parkinson's disease. *Lancet* pp. 2284–2303, <https://linkinghub.elsevier.com/retrieve/pii/S014067362100218X> (2021).
- Kafantari, E., Atterling Brolin, K., Wallenius, J., Swanberg, M. & Puschmann, A. WES-based screening of a Swedish patient series with Parkinson's disease. *Genes* **16**, 1482 (2025).
- Santiago, J. A. & Potashkin, J. A. Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes. *PLoS One* **8**(12), e83940 (2013).
- Szendroedi, J., Phielix, E. & Roden, M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. *Nat. Rev. Endocrinol.* **8**, 92–103 (2011).
- Cheong, J. L. Y., de Pablo-Fernandez, E., Foltynie, T. & Noyce, A. J. The association between Type 2 Diabetes Mellitus and Parkinson's disease. *J. Parkinsons Dis.* **10**, 775–789 (2020).
- Athauda, D. & Foltynie, T. Insulin resistance and Parkinson's disease: a new target for disease modification?. *Prog. Neurobiol.* **145–146**, 98–120 (2016).
- Aguirre-Vidal, Y., Montes, S., Mota-López, A. C. & Navarrete-Vázquez, G. Antidiabetic drugs in Parkinson's disease. *Clin. Park Relat. Disord.* **11**, 100265 (2024).
- Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. *Nat. Rev. Drug Discov.* **18**, 41–58 (2018).
- Zhu, S., Bai, Q., Li, L. & Xu, T. Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents. *Comput Struct. Biotechnol. J.* **20**, 2839 (2022).
- Tang, B. et al. Genetic variation in targets of antidiabetic drugs and alzheimer disease risk: a Mendelian randomization study. *Neurology* **99**, E650–E659 (2022).
- Birajdar, S. V., Mazahir, F., Alam, M. I., Kumar, A. & Yadav, A. K. Repurposing and clinical attributes of antidiabetic drugs for the treatment of neurodegenerative disorders. *Eur. J. Pharm.* **961**, 176117 (2023).
- Zhang, Y. et al. Metformin and the risk of neurodegenerative diseases in patients with diabetes: a meta-analysis of population-based cohort studies. *Diabet. Med.* **39**, e14821 (2022).
- Shi, Q., Liu, S., Fonseca, V. A., Thethi, T. K. & Shi, L. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. *BMJ Open* **9** <https://doi.org/10.1136/BMJOPEN-2018-024954> (2019).
- Wahlqvist, M. L. et al. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. *Parkinsonism Relat. Disord.* **18**, 753–758 (2012).
- Brauer, R. et al. Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes. *Brain* **143**, 3067–3076 (2020).
- McFarthing, K. et al. Parkinson's disease drug therapies in the clinical trial pipeline: 2024 update. *J. Parkinsons Dis.* **14**, 899–912 (2024).
- Sunnarborg, K. et al. Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes. *Pharmacoepidemiol Drug Saf.* **31**, 875 (2022).
- Lin, K. J. et al. Two birds one stone: the neuroprotective effect of antidiabetic agents on Parkinson disease—focus on sodium-glucose cotransporter 2 (SGLT2) inhibitors. *Antioxidants* **10**, <https://doi.org/10.3390/ANTIOX10121935> (2021).
- Daghlas, I. & Gill, D. Mendelian randomization as a tool to inform drug development using human genetics. *Camb. Prisms Precis. Med.* **1**, e16 (2023).
- Ebrahim, S. & Davey Smith, G. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology?. *Hum. Genet.* **123**, 15–33 (2008).
- Storm, C. S. et al. Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. *Nat. Commun.* **12**, 1–14 (2021).
- Mor, D. E. et al. Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria. *Proc. Natl. Acad. Sci. USA* **117**, 26438–26447 (2020).
- Zhao, Y., Fei, L. & Duan, Y. Movement disorders related to antidiabetic medications: a real-world pharmacovigilance study. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **135**, 111128 (2024).
- Liu, J., Shi, X. & Shao, Y. Sodium-glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: a Mendelian randomization study. *Brain Behav.* **14**, e3624 (2024).
- Aziz, N. A. & Wüllner, U. Genetic variants in sulfonylurea targets affect Parkinson's disease risk: a two-sample Mendelian randomization study. *Mov. Disord.* **38**, 703–705 (2023).
- Wang, Q. et al. Identifying potential repurposable medications for Parkinson's disease through Mendelian randomization analysis. *Sci. Rep.* **14**, 1–11 (2024).
- Domenighetti, C. et al. Association of Body Mass Index and Parkinson Disease A Bidirectional Mendelian Randomization Study. *Neurology* **10**, 103 (2024).
- Grover, S. et al. Genome-wide association and meta-analysis of age at onset in Parkinson disease: evidence from the COURAGE-PD Consortium. *Neurology* **99**, E698–E710 (2022).
- Landoulsi, Z. et al. Genome-wide association study of copy number variations in Parkinson's disease. *medRxiv* <https://www.medrxiv.org/content/10.1101/2024.08.21.24311915v2.full-text> (2025).
- Blauwendraat, C. et al. Parkinson's disease age at onset genome-wide association study: defining heritability, genetic loci, and α -synuclein mechanisms. *Mov. Disord.* **34**, 866–75 (2019).
- Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol.* **18**, 1091–1102 (2019).
- Magic Investigators - Data download. <https://magicinvestigators.org/downloads/> (2025).
- UK Biobank - UK Biobank. <https://www.ukbiobank.ac.uk/> (2025).
- Wu, Y. et al. Genome-wide association study of medication-use and associated disease in the UK Biobank. *Nat. Commun.* **10**, 1–10 (2019).
- Zheng, J. et al. Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study. *EBioMedicine* **96**, 104803 (2023).

37. Foretz, M., Guigas, B. & Viollet, B. Metformin: update on mechanisms of action and repurposing potential. *Nat. Rev. Endocrinol.* **19**, 460–76 (2023).
38. Gaal, O. I. et al. GWAS-identified hyperuricemia-associated IGF1R variant rs6598541 has a limited role in urate mediated inflammation in human mononuclear cells. *Sci. Rep.* **14**, 3565 (2024).
39. GTEx Portal. <https://www.gtexportal.org/home/downloads/adult-gtex/qtl> (2025).
40. Castilla-Cortázar, I., Aguirre, G. A., Femat-Roldán, G., Martín-Estal, I. & Espinosa, L. Is insulin-like growth factor-1 involved in Parkinson's disease development? *J. Transl. Med.* **18**, 1–17 (2020).
41. The Global Parkinson's Genetics Program (GP2) & Leonard, H. L. Novel Parkinson's disease genetic risk factors within and across European populations. *medRxiv*, <https://doi.org/10.1101/2025.03.14.24319455> (2025).
42. Kim, H. K. et al. SGLT2 inhibitor use and risk of dementia and Parkinson disease among patients with type 2 diabetes. *Neurology* **103**, e209805 (2024).
43. Zhao, H. et al. Thiazolidinedione use and risk of Parkinson's disease in patients with type 2 diabetes mellitus. *NPJ Parkinsons Dis.* **8**, 1–9 (2022). Dec 1.
44. Chen, L., Tao, Y., Li, J. & Kang, M. Pioglitazone use is associated with reduced risk of Parkinson's disease in patients with diabetes: a systematic review and meta-analysis. *J. Clin. Neurosci.* **106**, 154–8 (2022).
45. Qin, X. et al. Association between diabetes medications and the risk of Parkinson's disease: a systematic review and meta-analysis. *Front. Neurol.* **12**, 678649 (2021).
46. Tang, H. et al. Meta-analysis of association between newer glucose-lowering drugs and risk of Parkinson's disease. *Mov. Disord. Clin. Pr.* **10**, 1659–65 (2023).
47. Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. *Lancet* **390**, 1664–75 (2017).
48. Meissner, W. G. et al. Trial of lixisenatide in early Parkinson's disease. *N. Engl. J. Med.* **390**, 1176–85 (2024).
49. Vijjaratnam, N. et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. *Lancet* **405**, 627–36 (2025).
50. Zheng, G., Chattopadhyay, S., Sundquist, J., Sundquist, K. & Ji, J. Antihypertensive drug targets and breast cancer risk: a two-sample Mendelian randomization study. *Eur. J. Epidemiol.* **39**, 535–48 (2024).
51. Burgess, S. et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. *Wellcome Open Res.* **4**, 186 (2023).
52. Gill, D., Walker, V. M., Martin, R. M., Davies, N. M. & Tzoulaki, I. Comparison with randomized controlled trials as a strategy for evaluating instruments in Mendelian randomization. *Int. J. Epidemiol.* **49**, 1404–6 (2020).
53. Schmidt, A. F. et al. Genetic drug target validation using Mendelian randomisation. *Nat. Commun.* **11**, 1–12 (2020).
54. Gill, D. et al. Mendelian randomization for studying the effects of perturbing drug targets [version 1; peer review: awaiting peer review]. *Wellcome Open Res* **6**, 1–11 (2021).
55. PubChem. <https://pubchem.ncbi.nlm.nih.gov/> (2025).
56. DGIdb. <https://beta.dgidb.org/> (2025).
57. Chen, J. et al. The trans-ancestral genomic architecture of glycemic traits. *Nat. Genet.* **53**, 840–60 (2021).
58. Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–5 (2013).
59. Quiver, M. H. & Lachance, J. Adaptive eQTLs reveal the evolutionary impacts of pleiotropy and tissue-specificity while contributing to health and disease. *Hum. Genet. Genomics Adv.* **3**, 100083 (2021).
60. Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* **613**, 508–18 (2023).
61. Trait: Childhood asthma (age<16) - IEU OpenGWAS project. https://gwas.mrcieu.ac.uk/datasets/ukb-d-ASTHMA_CHILD/ (2025).
62. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. *eLife* **7**, e34408 (2018). 2018.
63. R Core Team. *R: A Language and Environment for Statistical Computing* (R Foundation for Statistical Computing, 2023).
64. Durinck, S. et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. *Bioinformatics* **21**, 3439–40 (2005).
65. Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* **4**, 1184–91 (2009).
66. Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).

Acknowledgements

The project was funded by the Swedish Research Council (2022-01099), Grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (FoUI-1000568), the Swedish Parkinson Foundation (1573/24), K.W. was supported by Region Stockholm (clinical research appointment). The authors would also like to thank the patients and research participants for contributing their data, as well as the medical staff, database managers, research infrastructure facilitators, funding bodies, colleagues, and the wider research community.

Author contributions

Conceptualization K. Vincze, X. Kang, K. Wirdefeldt. Methodology K. Vincze, A. Szwajda, A. Ploner, X. Kang, R. Karlsson, B. Tang, S. Hägg, K. Wirdefeldt. Software K. Vincze, A. Szwajda, A. Ploner, X. Kang, R. Karlsson, B. Tang, C. Qin. Validation K. Vincze, A. Szwajda, A. Ploner, S. Carlsson, S. Hägg, K. Wirdefeldt. Formal analysis K. Vincze. Investigation K. Wirdefeldt, N. L. Pedersen and all authors in the list from C. Domenighetti to M. Sharma (COURAGE-PD authors). Resources S. Hägg, N. L. Pedersen, K. Wirdefeldt and COURAGE-PD authors. Data Curation K. Vincze, A. Szwajda, A. Ploner, X. Kang, K. Wirdefeldt and COURAGE-PD authors. Writing - Original Draft K. Vincze. Writing - Review & Editing All authors. Visualization K. Vincze, A. Szwajda, A. Ploner. Supervision S. Carlsson, S. Hägg, K. Wirdefeldt. Project administration K. Vincze and K. Wirdefeldt. Funding acquisition K. Wirdefeldt. All authors reviewed the manuscript.

Funding

Open access funding provided by Karolinska Institute.

Competing interests

C.Q. is currently working at Novo Nordisk, but the study was designed during her postdoctoral research at Karolinska Institutet. Novo Nordisk did not influence the submitted work. A.B.S. reports grants from Department of Defense, during the conduct of the study; grants from Michael J Fox Foundation, outside the submitted work. A.B.S. is an unpaid Scientific Advisory Board member for Cajal Neuroscience outside of the submitted work. A.B.S. is part of the Editorial board of Neurogenetics. A.B.S. was not involved in the journal's review of, or decisions related to, this manuscript. W.P. reports personal fees from Grünenthal, personal fees from AbbVie, personal fees from AOP Health Orphan, personal fees from Zambon, personal fees and other from Boehringer Ingelheim, personal fees from Stada, personal fees from Bial UCB Pharma, outside the submitted work. A.E.L. reports personal fees from AbbVie, personal fees from AFFIRIS, personal fees from Janssen, personal fees from Biogen, personal fees from Merck, personal fees from Sun Pharma, personal fees from Corticobasal Solutions, personal fees from Sunovion, personal fees from Paladin, personal fees from Lilly, personal fees from Medtronic, personal fees from Theravance, personal fees from Lundbeck, personal fees from Retrophin,

personal fees from Roche, personal fees from PhotoPharmics, outside the submitted work. P. T. was supported by the Grants PRG2736 and TEM-TA110 of the Estonian Research Council. A.B. reports grants from France Parkinson + FRC, grants from ANR - EPIG - Agence nationale de recherche, grants from ANR - JPND - Agence nationale de recherche, grants from RDS (Roger de Spoelberch Foundation), grants from France Alzheimer, grants from Institut de France, grants from ANR - EPIG, grants from FMR (maladies rares), outside the submitted work. A.B. is part of the editorial advisory board of Brain, as well as the Editorial board of Neurogenetics. A.B. was not involved in the journal's review of, or decisions related to, this manuscript. J.C.C. reports grants from the Michael J Fox Foundation, Sanofi, and served in advisory boards for Air Liquide, Biogen, Denali, Ever Pharma, Idorsia, Prevail Therapeutic, Theranexus, UCB, outside the submitted work. K.B. has received research funding from the Michael J. Fox Foundation for Parkinson's Research (MJFF-022343, MJFF-023275, MJFF-023365), the German Society for Parkinson DPG, the Health Forum Baden Wuerttemberg, the Else Kröner Fresenius Stiftung (ClinbrAln), the University of Tuebingen, and from the German Research Foundation DFG (BR-655671-1. K.B. is a consultant for F. Hoffmann-La Roche Ltd., Vanqua Bio, and the Michael J. Fox Foundation for Parkinson's Research and has received speaker honoraria from Abbvie, Lundbeck, UCB and Zambon.' L.S. reports the following grants: PPMI2 (supported by the Michael J. Fox Foundation), IMPRIND-IMI2 Number 116060 (EU, H2020), "Transferring autonomous and non-autonomous cell degeneration 3D models between EU and USA for development of effective therapies for neurodegenerative diseases (ND) - CROSS NEUROD" (H2020-EU 1.3.3., Grant Number778003), «Chaperone-Mediated Autophagy in Neurodegeneration» (Hellenic Foundation for Research and Innovation Grant HFRI-FM17-3013), and "CMA as a Means to Counteract alpha-Synuclein Pathology in Non-Human Primates" Grant by the Michael J. Fox Foundation (Collaborator). L.S. is co-Head and PI at the NKUA of the General Secretariat of Research and Technology (GSRT)-funded Grant "National Network of Precision Medicine for Neurodegenerative Diseases". L.S. has served on an Advisory Board for Abbvie, ITF Hellas and Biogen and has received honoraria from Abbvie and Sanofi. There are no specific disclosures related to the current work. E.M.V. serves as Associate Editor of Journal of Medical Genetics, Section Editor of Pediatric Research, Member of the Editorial Board of Movement Disorders Clinical Practice; grants from the Italian Ministry of Health, CARIPO Foundation, Pierfranco and Luisa Mariani Foundation, Telethon Foundation Italy, outside the submitted work. E.M.V. was not involved in the journal's review of, or decisions related to, this manuscript. N.H. reports grants from - Japan Agency for Medical Research and Development (AMED), grants from - Japan Society for the Promotion of Science (JSPS), grants from - Ministry of Education Culture, Sports, Science and Technology Japan; Grant-in-Aid for Scientific Research on Innovative Areas, personal fees and other from Dai-Nippon Sumitomo Pharma Co.,Ltd, personal fees and other from Takeda Pharmaceutical Co.,Ltd., personal fees and other from Kyowa Kirin Co.,Ltd., personal fees and other from GSK K.K, personal fees and other from Nippon Boehringer Ingelheim,Co.,Ltd, personal fees and other from FP Pharmaceutical Corporation, personal fees and other from Eisai Co.,Ltd., personal fees and other from Kissei Pharmaceutical Company, personal fees and other from Nihon Medi-physics Co.,Ltd, personal fees and other from Novartis Pharma K.K, personal fees and other from Biogen Idec Japan Ltd, personal fees and other from AbbVie, from Medtronic, Inc., other from Boston Scientific Japan, personal fees and other from Astellas Pharma Inc., grants and other from Ono Pharmaceutical Co.,Ltd, other from Nihon Pharmaceutical Co., Ltd, other from Asahi Kasei Medical Co.,Ltd, other from Mitsubishi Tanabe Pharma Corporation, personal fees and other from Daiichi Sankyo Co., other from OHARA Pharmaceutical Co.,Ltd, other from Meiji Seika Pharma, personal fees from Sanofi K.K., personal fees from Pfizer Japan Inc., personal fees from Alexion Pharmaceuticals, personal fees from Mylan N.V, personal fees from MSD K.K, personal fees from Lund Beck Japan, other from Hisamitsu Pharmaceutical Co.,Inc, outside the submitted work. K.N. reports grants from - Japan Society for the Promotion of Science (JSPS), outside the submitted work. P.K. reports other from Centre

Hospitalier de Luxembourg; University of Luxembourg, grants from Fonds National de Recherche (FNR), from null, outside the submitted work. B.P.C.v.d.W. reports grants from ZonMw, Hersenstichting, Gossweiler Fund, Radboud university medical centre, and Christina Foundation outside the submitted work. B.P.C.v.d.W. has done paid consultancy for Biohaven Pharmaceuticals, Vico Therapeutics, and Servier, and receives royalties from BSL/Springer-Nature. B.R.B. reports grants from Netherlands Organization for Health Research and Development, grants from Michael J. Fox Foundation, grants from Parkinson Vereniging, grants from Parkinson Foundation, grants from Gatsby Foundation, grants from Verily Life Sciences, grants from Horizon 2020, grants from Topsector Life sciences and Health, grants from Stichting Parkinson Fonds, grants from UCB, grants from Abbvie, during the conduct of the study; personal fees from Biogen, personal fees from Abbvie, personal fees from Walk with Path, personal fees from UCB, personal fees from Abbvie, personal fees from Zambon, personal fees from Bial, personal fees from Roche, outside the submitted work; and Serves as editor-in-chief of the Journal of Parkinson's Disease and serves on the editorial board of Practical Neurology and Digital Biomarkers. B.R.B. was not involved in the journal's review of, or decisions related to, this manuscript. M.T. reports grants from Research Council of Norway, during the conduct of the study; grants from South-Eastern Norway Regional Health Authority, grants from Michael J. Fox Foundation, outside the submitted work. L.P. reports grants from Norwegian Health Association, grants from South-Eastern Norway Regional Health Authority, outside the submitted work. J.J.F. reports grants from GlaxoSmithKline, grants from Grunenthal, grants from Fundação MSD (Portugal), grants from TEVA, grants from MSD, grants from Allergan, grants from Novartis, grants from Medtronic, grants from GlaxoSmithKline, grants from Novartis, grants from TEVA, grants from Lundbeck, grants from Solvay, grants from BIAL, grants from Merck-Serono, grants from Merz, grants from Ipsen, grants from Biogen, grants from Acadia, grants from Allergan, grants from Abbvie, grants from Sunovion Pharmaceuticals, personal fees from Faculdade de Medicina de Lisboa, personal fees from CNS - Campus Neurológico Sênior, personal fees from BIAL, personal fees from Novartis, outside the submitted work. S.B. is supported by the National Research Foundation of South Africa (Grant 129249) and the South African Medical Research Council (Self-Initiated Research Grant). E.T. received honoraria for consultancy from TEVA, Bial, Prevail Therapeutics, Boehringer Ingelheim, Roche and BIOGEN and has received funding for research from Spanish Network for Research on Neurodegenerative Disorders (CIBERNED)- Instituto Carlos III (ISCIII), and The Michael J. Fox Foundation for Parkinson's Research(MJFF). A.P. reports grants from Parkinsonfonden (The Swedish Parkinson Foundation), grants from ALF (Swedish Government), grants from Region Skåne, Sweden, grants from Skåne University Hospital, grants from Hans-Gabriel och Trolle Wachtmeister Stiftelse för Medicinsk Forskning, Sweden, grants from Multipark – a strategic research environment at Lund University, during the conduct of the study; personal fees from Elsevier, outside the submitted work.M.T. reports grants from Parkinson's UK, other from Michael J Fox Foundation, other from University College London, outside the submitted work. D.K. is Associate Editor of The Journal of Clinical Investigation. D.K. was not involved in the journal's review of, or decisions related to, this manuscript. D.K. is also a Venture Partner at OrbiMed, founder and SAB chair at Vanqua BIO, founder of LTI, outside the submitted work. R.K. reports grants from Fonds National de Recherche (FNR), grants from German Research Council (DFG), non-financial support from Abbvie, Zambon, during the conduct of the study; personal fees from University of Luxembourg; Luxembourg Institute of Health; Centre Hospitalier de Luxembourg, grants from Fonds National de Recherche, Luxembourg (FNR), grants from Fonds National de Recherche, Luxembourg (FNR), grants from Fonds National de Recherche (FNR), Luxembourg/German Research Council (DFG), grants from Fonds National de Recherche, Luxembourg (FNR), personal fees from Desitin/Zambon, personal fees from Abbvie GmbH, personal fees from Medtronic GmbH, outside the submitted work. T.G. reports personal fees from UCB Pharma, personal fees from Novartis, personal fees from Teva, personal fees from MedUpdate, grants from The Michael J Fox Foundation

for Parkinson's Research, grants from Bundesministerium für Bildung und Forschung (BMBF), grants from Deutsche Forschungsgemeinschaft (DFG), other from "Joint Programming for Neurodegenerative Diseases"(JPND) program, funded by the European Commission, outside the submitted work; In addition, T.G. has a patent. Patent Number: EP1802749 (A2) KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders issued. T.G. is on the Editorial board of Neurogenetics. T.G.r was not involved in the journal's review of, or decisions related to, this manuscript. A.E. reports grants from Agence nationale de recherche (ANR), Michael J Fox foundation, Plan Ecophyto (French ministry of agriculture), and France Parkinson, outside the submitted work. M.S. reports grants from German Research Council (DFG) (SH 599/16-1), Michael J Foundation (MJFF), and GP2. N.L.P. reports grants from Swedish Research Council, during the conduct of the study. K.W. reports grants from Swedish Research Council, during the conduct of the study. K.W. was supported by Region Stockholm (clinical research appointment). The other authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41531-026-01398-5>.

Correspondence and requests for materials should be addressed to Katalin Vincze.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026

Katalin Vincze¹ ✉, Agnieszka Sz wajda¹, Alexander Ploner¹, Robert Karlsson¹, Xiaoying Kang¹, Bowen Tang^{1,2}, Chenxi Qin¹, Cloé Domenighetti³, Pierre-Emmanuel Sugier³, Ashwin Ashok Kumar Sreelatha⁴, Claudia Schulte^{5,6}, Berta Portugal³, Patrick May⁷, Dheeraj Reddy Bobbili⁸, Milena Radivojkov-Blagojevic⁹, Peter Lichtner⁹, Andrew B. Singleton^{10,11}, Dena G. Hernandez¹⁰, Connor Edsall¹⁰, George D. Mellick¹², Alexander Zimprich¹³, Walter Pirker¹⁴, Ekaterina Rogaeva¹⁵, Anthony E. Lang^{16,17}, Sulev Koks^{18,19}, Pille Taba^{20,21}, Suzanne Lesage²², Alexis Brice²², Jean-Christophe Corvol^{22,23}, Marie-Christine Chartier-Harlin²⁴, Eugénie Mutez²⁴, Kathrin Brockmann^{5,6}, Angela B. Deutschlander^{25,26}, Lena F. Burbulla²⁷, Georges M. Hadjigeorgiou^{28,29}, Efthimos Dardiotis²⁹, Leonidas Stefanis^{30,31}, Athina Maria Simitsi³¹, Enza Maria Valente^{32,33}, Simona Petrucci^{34,35}, Letizia Straniero³⁶, Anna Zecchinelli³⁷, Gianni Pezzoli³⁸, Laura Brighina^{39,40}, Carlo Ferrarese^{39,40}, Grazia Annesi⁴¹, Andrea Quattrone⁴², Monica Gagliardi⁴³, Hirotaka Matsuo⁴⁴, Akiyoshi Nakayama⁴⁴, Nobutaka Hattori⁴⁵, Kenya Nishioka⁴⁵, Sun Ju Chung⁴⁶, Yun Joong Kim⁴⁷, Pierre Kolber⁴⁸, Bart PC Van de Warrenburg⁴⁹, Bastiaan R. Bloem⁴⁹, Mathias Toft⁵⁰, Lasse Pihlstrøm⁵⁰, Leonor Correia Guedes^{51,52}, Joaquim J. Ferreira^{51,53}, Soraya Bardien^{54,55}, Jonathan Carr⁵⁶, Eduardo Tolosa^{57,58}, Mario Ezquerra⁵⁹, Pau Pastor^{60,61}, Caroline Ran⁶², Andrea C. Belin⁶², Andreas Puschmann^{63,64}, Carl E. Clarke^{65,66}, Karen E. Morrison⁶⁷, Manuela Tan⁶⁸, Dimitri Krainc⁶⁹, Matt J. Farrer⁷⁰, Zied Landoulsi^{7,71}, Rejko Kruger^{7,71}, Thomas Gasser^{5,6}, Alexis Elbaz³, Manu Sharma⁴, Nancy L. Pedersen¹, Sofia Carlsson², Sara Hägg¹, Karin Wirdefeldt^{1,72}

On behalf of the Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD) Consortium Cloé Domenighetti³, Pierre-Emmanuel Sugier³, Ashwin Ashok Kumar Sreelatha⁴, Claudia Schulte^{5,6}, Berta Portugal³, Patrick May⁷, Dheeraj Reddy Bobbili⁸, Milena Radivojkov-Blagojevic⁹, Peter Lichtner⁹, Andrew B. Singleton^{10,11}, Dena G. Hernandez¹⁰, Connor Edsall¹⁰, George D. Mellick¹², Alexander Zimprich¹³, Walter Pirker¹⁴, Ekaterina Rogaeva¹⁵, Anthony E. Lang^{16,17}, Sulev Koks^{18,19}, Pille Taba^{20,21}, Suzanne Lesage²², Alexis Brice²², Jean-Christophe Corvol^{22,23}, Marie-Christine Chartier-Harlin²⁴, Eugénie Mutez²⁴, Kathrin Brockmann^{5,6}, Angela B. Deutschlander^{25,26}, Lena F. Burbulla²⁷, Georges M. Hadjigeorgiou^{28,29}, Efthimos Dardiotis²⁹, Leonidas Stefanis^{30,31}, Athina Maria Simitsi³¹, Enza Maria Valente^{32,33}, Simona Petrucci^{34,35}, Letizia Straniero³⁶, Anna Zecchinelli³⁷, Gianni Pezzoli³⁸, Laura Brighina^{39,40}, Carlo Ferrarese^{39,40}, Grazia Annesi⁴¹, Andrea Quattrone⁴², Monica Gagliardi⁴³, Hirotaka Matsuo⁴⁴, Akiyoshi Nakayama⁴⁴, Nobutaka Hattori⁴⁵, Kenya Nishioka⁴⁵, Sun Ju Chung⁴⁶, Yun Joong Kim⁴⁷, Pierre Kolber⁴⁸, Bart PC Van de Warrenburg⁴⁹, Bastiaan R. Bloem⁴⁹, Mathias Toft⁵⁰, Lasse Pihlstrøm⁵⁰, Leonor Correia Guedes^{51,52}, Joaquim J. Ferreira^{51,53}, Soraya Bardien^{54,55}, Jonathan Carr⁵⁶, Eduardo Tolosa^{57,58}, Mario Ezquerra⁵⁹, Pau Pastor^{60,61}, Caroline Ran⁶², Andrea C. Belin⁶², Andreas Puschmann^{63,64}, Carl E. Clarke^{65,66}, Karen E. Morrison⁶⁷, Manuela Tan⁶⁸, Dimitri Krainc⁶⁹, Matt J. Farrer⁷⁰, Zied Landoulsi^{7,71}, Rejko Kruger^{7,71}, Thomas Gasser^{5,6}, Alexis Elbaz³, Manu Sharma⁴ & Karin Wirdefeldt^{1,72}

¹Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ²Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden. ³Gustave Roussy, University of Paris-Saclay, UVSQ, Inserm, Villejuif, France. ⁴University of Tübingen, Institute for Clinical Epidemiology and Applied Biometry, Centre for Genetic Epidemiology, Tübingen, Germany. ⁵Department for Neurodegenerative Diseases, University of Tübingen, Hertie Institute for Clinical Brain Research, Tübingen, Germany. ⁶German Center for Neurodegenerative Diseases, Tübingen, Germany. ⁷University of Luxembourg, Luxembourg Centre for Systems Biomedicine (LCSB), Translational Neuroscience, Luxembourg, Luxembourg. ⁸Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Luxembourg, Luxembourg. ⁹Helmholtz Zentrum München, Institute of Human Genetics, Munich, Germany. ¹⁰National Institutes of Health, Laboratory of Neurogenetics, Molecular Genetics Section, Bethesda, MD, USA. ¹¹National Institutes of Health, Center For Alzheimer's and Related Dementias, Bethesda, MD, USA. ¹²Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD, Australia. ¹³Department of Neurology, Medical University of Vienna, Vienna, Austria. ¹⁴Department of Neurology, Klinik Ottakring, Vienna, Austria. ¹⁵Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada. ¹⁶Toronto Western Hospital, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto, ON, Canada. ¹⁷Division of Neurology, University of Toronto, Toronto, ON, Canada. ¹⁸Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, WA, Australia. ¹⁹Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia. ²⁰Institute of Clinical Medicine, University of Tartu, Faculty of Medicine, Tartu, Estonia. ²¹Clinic of Neurology, Tartu University Hospital, Tartu, Estonia. ²²Department of Neurologie, Sorbonne University, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Paris, France. ²³Assistance Publique Hôpitaux de Paris, Department of Neurology, CIC Neurosciences, Paris, France. ²⁴Centre de Recherche Lille Neurosciences & Cognition, University of Lille, Inserm, Lille, France. ²⁵Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany. ²⁶Department of Neurology, Max Planck Institute of Psychiatry, Munich, Germany. ²⁷Metabolic Biochemistry, Ludwig-Maximilians-Universität München, Faculty of Medicine, Biomedical Center, Munich, Germany. ²⁸Department of Neurology, University of Cyprus, Medical School, Nicosia, Cyprus. ²⁹Laboratory of Neurogenetics, University Hospital of Larissa, University of Thessaly, Department of Neurology, Larissa, Greece. ³⁰Biomedical Research Foundation of the Academy of Athens, Experimental Surgery and Translational Research, Center of Clinical Research, Athens, Greece. ³¹1st Department of Neurology, National and Kapodistrian University of Athens, Medical School, Eginition Hospital, Athens, Greece. ³²Department of Molecular Medicine, University of Pavia, Pavia, Italy. ³³Mondino Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Pavia, Italy. ³⁴Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy. ³⁵UOC Medical Genetics and Advanced Cell Diagnostics, S. Andrea University Hospital, Rome, Italy. ³⁶Department of Biomedical Sciences, Humanitas University, Milan, Italy. ³⁷Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Parkinson Institute, Milan, Italy. ³⁸Fontazione Grigioni, Parkinson Institute, Milan, Italy. ³⁹Department of Neurology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. ⁴⁰Department of Medicine and Surgery and Milan Center for Neuroscience, University of Milano-Bicocca, Milan, Italy. ⁴¹National Research Council, Cosenza, Italy. ⁴²Department of Medical and Surgical Sciences, Institute of Neurology, Magna Graecia University, Catanzaro, Italy. ⁴³Department of Medical and Surgical Sciences, Neuroscience Research Center, Magna Graecia University, Catanzaro, Italy. ⁴⁴Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama, Japan. ⁴⁵Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan. ⁴⁶Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. ⁴⁷Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea. ⁴⁸Centre Hospitalier de Luxembourg, Neurology, Luxembourg, Luxembourg. ⁴⁹Department of Neurology, Radboud University Nijmegen Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Netherlands. ⁵⁰Department of Neurology, Oslo University Hospital, Oslo, Norway. ⁵¹Instituto de Medicina Molecular João Lobo Antunes, University of Lisbon, Faculty of Medicine, Lisbon, Portugal. ⁵²Department of Neurosciences and Mental Health, Neurology, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal. ⁵³Laboratory of Clinical Pharmacology and Therapeutics, University of Lisbon, Faculty of Medicine, Lisbon, Portugal. ⁵⁴Department of Biomedical Sciences, Division of Molecular Biology and Human Genetics, Stellenbosch University, Faculty of Medicine and Health Sciences, Cape Town, South Africa. ⁵⁵South African Medical Research Council/Stellenbosch University Genomics of Brain Disorders Research Unit, Stellenbosch University, Cape Town, South Africa. ⁵⁶Department of Medicine, Division of Neurology, Stellenbosch University, Faculty of Medicine and Health Sciences, Stellenbosch, South Africa. ⁵⁷Parkinson's disease & Movement Disorders Unit, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Neurology Service, Barcelona, Spain. ⁵⁸Centro de Investigación Biomédica en Red, Enfermedades Neurodegenerativas, Barcelona, Spain. ⁵⁹Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, University of Barcelona, Institut de Neurociències, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. ⁶⁰Fundació per la Recerca Biomèdica i Social Mútua Terrassa, Barcelona, Spain. ⁶¹Department of Neurology, Movement Disorders Unit, University Hospital Mútua de Terrassa, Terrassa, Spain. ⁶²Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. ⁶³Department of Clinical Sciences Lund, Division of Neurology, Lund University, Lund, Sweden. ⁶⁴Department of Neurology, Skåne University Hospital, Lund, Sweden. ⁶⁵University of Birmingham, Birmingham, United Kingdom. ⁶⁶Sandwell & West Birmingham Hospitals NHS Trust, West Bromwich, United Kingdom. ⁶⁷Health and Life Sciences, Faculty of Medicine, Queens University, Belfast, United Kingdom. ⁶⁸Department of Clinical and Movement Neurosciences, University College London, UCL Queen Square Institute of Neurology, London, United Kingdom. ⁶⁹Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ⁷⁰Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, FL, USA. ⁷¹Luxembourg Institute of Health, Transversal Translational Medicine, Strassen, Luxembourg. ⁷²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

✉ e-mail: katalin.vincze@ki.se